PubRank

Dariush Etemadmoghadam

Author PubWeight™ 62.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International network of cancer genome projects. Nature 2010 20.35
2 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008 8.17
3 Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 5.28
4 Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010 5.23
5 Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009 4.30
6 Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2012 3.64
7 High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007 1.65
8 Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011 1.57
9 Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 2013 1.54
10 Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 2010 1.50
11 SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010 1.42
12 Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol 2012 1.41
13 LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res 2012 1.39
14 Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012 1.35
15 Profiling the cancer genome. Annu Rev Genomics Hum Genet 2010 1.22
16 Stanniocalcin-1, an inhibitor of macrophage chemotaxis and chemokinesis. Am J Physiol Renal Physiol 2003 1.18
17 Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res 2013 1.09
18 Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One 2011 0.96
19 Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. Immunol Cell Biol 2006 0.85
20 High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One 2013 0.82
21 Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015 0.75